Jeffery S. Loutit
Nessuna posizione attualmente
Profilo
Jeffery S.
Loutit was the founder and had founded Rempex Pharmaceuticals, Inc. in 2011, where he held the title of Chief Medical Officer from 2011 to 2013.
Dr. Loutit's former jobs include Vice President-Clinical Science at InterMune, Inc., Assistant Professor-Medicine at Stanford University, and Chief Medical Officer at MPEX Pharmaceuticals, Inc. Dr. Loutit received a doctorate degree from the University of Otago.
Precedenti posizioni note di Jeffery S. Loutit
Società | Posizione | Fine |
---|---|---|
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Fondatore | 01/12/2013 |
INTERMUNE INC | Corporate Officer/Principal | - |
Stanford University | Corporate Officer/Principal | - |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Jeffery S. Loutit
University of Otago | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Jeffery S. Loutit